S-095024

N/A

Report date: 2026/02/14 20:00:22

Base Information

Drug NameS-095024
Drug Alias NameAnti-CD73 antibodytherapy(Servier Bio-Innovation)S095024S-095024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-5'-nucleotidase
Targets5'-nucleotidase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitut De Recherches Internationales ServierServier Bio-Innovation LLCRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesServier Bio-Innovation LLCInstitut De Recherches Internationales ServierRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A